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0929-6646/Copyright ª 2015, FormosaAlzheimer’s disease (AD) is a neurodegenerative disorder in which the death of brain cells
causes memory loss and cognitive decline, i.e., dementia. The disease starts with mild symp-
toms and gradually becomes severe. AD is one of the leading causes of mortality worldwide.
Several different hallmarks of the disease have been reported such as deposits of b-amyloid
around neurons, hyperphosphorylated tau protein, oxidative stress, dyshomeostasis of bio-
metals, low levels of acetylcholine, etc. AD is not simple to diagnose since there is no single
diagnostic test for it. Pharmacotherapy for AD currently provides only symptomatic relief
and mostly targets cognitive revival. Computational biology approaches have proved to be reli-
able tools for the selection of novel targets and therapeutic ligands. Molecular docking is a key
tool in computer-assisted drug design and development. Docking has been utilized to perform
virtual screening on large libraries of compounds, and propose structural hypotheses of how
the ligands bind with the target with lead optimization. Another potential application of dock-
ing is optimization stages of the drug-discovery cycle. This review summarizes the known drug
targets of AD, in vivo active agents against AD, state-of-the-art docking studies done in AD, and
future prospects of the docking with particular emphasis on AD.
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Alzheimer’s disease (AD) is one of the most common causes
of dementia in the society. AD is generally classified into
two types: (1) early onset/familial AD (FAD); and (2) spo-
radic AD (SAD).1 The malfunctioning and gradual death of
neurons in the disease results in loss of memory and
cognitive functions. The disease is characterized by accel-
erated accumulation of amyloid b (Ab) plaque around
neurons and hyperphosphorylated microtubule associated
tau protein in the form of neurofibrillary tangles within the
cells.2,3 The degradation of hyperphosphorylated tau by the
proteasome system is also inhibited by the actions of Ab.
Amyloidogenic pathway results from a mutation and re-
places the normal pathway in which a-secretase acts on the
amyloid precursor protein (APP), a membrane protein,
followed by g-secretase forming a harmless peptide but the
amyloidogenic pathway involves the breakdown of APP by
b-secretase followed by g-secretase, and results in the
formation of Ab plaque, whose major constituent is the 42
residue long Ab42.4,5 AD is a progressive neurodegenerative
disorder characterized by progressive loss of memory,
declining cognitive function, decreased physical function,
and ultimately the patient’s death due to the death of the
brain cells (Fig. 1).6 The progression of AD can be broken
into three basic stages: (1) preclinical (no signs or symp-
toms); (2) mild cognitive impairment; and (3) dementia.7Figure 1 Alzheimer’s frRecent reports suggest that > 4.7 million people of  65
years of age are living with AD in the USA.8 AD is predicted
to affect one in 85 people globally by 2050.9,10
Ab oligomers and plaques are potent synaptotoxins,
block proteasome function, inhibit mitochondrial activity,
alter intracellular Ca2þ levels,11,12 and stimulate inflam-
matory processes.13,14 The above processes contribute to
neuronal dysfunction. Hyperphosphorylation of tau protein
leads to the accumulation of neurofibrillary tangles within
the neurons.3 As a result the biochemical and synaptic
communication between neurons is disrupted which results
in the gradual death of the cells.15 The majority of the
cases of AD are SAD.16 FAD is caused by autosomal dominant
mutations in either APP or the presenilin-1 or -2 gene/
protein.17,18 A gene known as the Apo-ε4 is one of the
factors associated with higher chances of sporadic AD.19
The risk factors for SAD include aging leading to a gradual
deterioration of function, presence of the apolipoprotein
E4 (APOE4) allele, and vascular diseases such as stroke and
cardiac disease.20,21
Computer-aided drug design or computational drug dis-
covery has been one of the major tools applied in drug
discovery programs used to reduce the cost and process
time. The major parts of computer-aided drug design are
structure based drug design, ligand based drug design, and
sequence based approaches. The most widely used chain
for drug discovery and designing seems to be targetom disease to death.
Therapeutic approaches for Alzheimer’s disease 5identificationdmolecular dockingdquantitative structure-
activity relationshipdlead optimization. Docking is a
computational approach that predicts the favored orien-
tation of the binding of one molecule (ligand) to the second
molecule (receptor) to form a stable or firm complex.
Docking is a software based program used to envisage the
affinity and activity of binding of small molecules to their
targets by using scoring functions. Molecular docking soft-
ware has two core components: (1) a search algorithm
(used to find the best conformations of the ligand and re-
ceptor); and (2) score function (a measure of how strongly a
given ligand will interact with a particular receptor).22,23
This review is strongly focused on targets, ligands, and
docking advances which have been used to search the best
inhibitors or stimulators for AD therapy (Fig. 2).Conventional drug target networks in AD
Acetylcholinesterase
Damage to the acetylcholine (ACh) producing cholinergic
neurotransmission has been shown to be possibly associated
with the memory deficits in the brain of patients with AD.24
Some forms of learning and plasticity in the brain cortex are
dependent on the presence of ACh.25,26 The neurotrans-
mitter ACh is released from nerve fibers during cholinergic
transmission, which binds to the designated receptors on
other cholinergic nerve fibers and conveys the message to
generate a response. The cholinesterase enzymes [mainly
acetylcholinesterase (AChE) present in the synaptic cleft of
cholinergic neurons] decrease the concentration of ACh by
hydrolyzing the molecule.27 Cholinesterase inhibitors bind
to these enzymes resulting in increased concentration ofFigure 2 Major targets in Alzheimer’s disease therapy. AChE Z
mAChR Z muscarinic acetylcholine receptors; NMDA Z N-methyl-DACh in the synapses.28 The resulting accumulation of ACh
causes continuous stimulation of the muscles and glands
that potentiate the parasympathetic activities like vasodi-
latation, constriction of pupils of the eyes, increased pro-
duction of sweat, saliva, and tears, slow heart rate, mucus
secretion in the respiratory tract, and constriction of
bronchioles.29 The development of AChE inhibitors is based
on the finding that disruption of the cholinergic pathways in
the cerebral cortex and basal forebrain contributes to the
cognitive impairment of AD patients.30,31 There are
currently four drugs that act as an AChE inhibitor and are
approved for symptomatic relief; namely donepezil, gal-
antamine, rivastigmine, and tacrine.32
Computational biology approaches, primarily drug
designing and molecular docking, have opened a new way
for designing and developing more potent targets against
disease. Besides the above marketed AChE inhibitors, many
new modified synthetic and natural compounds have been
shown to have potential cholinesterase activity. The pres-
ence of peripheral anionic site (PAS), besides the catalytic
site on AChE, has been implied in promoting amyloid fibril
formation and its colocalization. Novel flavonoid de-
rivatives have been designed which can bind to both the
mentioned sites of AChE and inhibited it better as
compared with the conventional rivastigmine and donepe-
zil.33 In another study, derivatives of four flavonoids namely
quercetin, rutin, kaempferol, and macluraxanthone were
tested chemically and computationally. Macluraxanthone
and quercetin derivatives were found to have very good
inhibitory activity against the cholinesterase.34 Several
modified novel carbamates have been synthesized and have
been tested in silico and in vitro and have been found to
have very good AChE inhibitory activity.35 Some novel
compounds such as pyridopyrimidine, synthesized in vitro,acetylcholinesterase; GSK-3 Z glycogen synthase kinase-3;
-aspartate.
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the marketed drug galantamine, as reported through the
molecular docking as well as in vitro studies.36 Recently
pyridonepezil and 6-chloro-pyridonepezil (the hybrid of
donepezil and aminopyridine) have been reported to be
more potent cholinesterase inhibitors than the single
donepezil molecule through various in silico and in vitro
studies. These compounds are considered to be dual in-
hibitors as they bind to both the catalytic site and the
PAS.37,38 Many piperazine derivatives were also reported by
researchers to be AChE inhibitors and a few were dual-site
inhibitors as well.39N-methyl-D-aspartate receptor
Excessive activation of N-methyl-D-aspartate (NMDA) type
glutamate receptors causes excessive and continuous Ca2þ
influx through the receptor associated ion channel in AD
patients.40 Glutamate-mediated synaptic transmission is
vital for the normal functioning of the nervous system with
glutamate being the most important excitatory neuro-
transmitter in the brain.41 Hyperactivation of the NMDA
receptor with glutamate leads to the production of free
radicals and other enzymes that contribute to the death of
neuronal cells. Glutamate is not eliminated properly and
may even be inappropriately released, with the disruption
of energy metabolism during acute and chronic neurode-
generative disorders. Furthermore, energetically compro-
mised neurons become depolarized since in the absence of
energy they cannot maintain ionic homeostasis. This de-
polarization relieves the normal Mg2þ block of NMDA
receptor-coupled channels.42 Consequently, during
ischemia and other neurodegenerative symptoms, exces-
sive stimulation of glutamate receptors is supposed to
occur. Therefore, NMDA receptor antagonists could be
therapeutically beneficial in a number of neurological dis-
orders like stroke, dementia, and neuropathic pain syn-
dromes.43 NMDA receptors are made up of different
subunits like NR1 and NR2A-D (NR3A or B subunits in some
cases also). The receptor is composed of a tetramer of
these subunits. The subunit composition determines the
pharmacology and other parameters of the receptor-ion
channel complex. The alternative splicing of subunits,
such as NR1, further contributes to the pharmacological
properties of the receptor.44 The drug memantine (the only
marketed NMDA receptor antagonist) has a rapid blocking
and unblocking activity with the receptor.45 Since mem-
antine is the single drug molecule available as the NMDA
antagonist, a wide range of molecular docking studies are in
the pipeline to select a number of novel and active ligands
against this receptor in AD. In this process, some of the
major novel ligands identified as having validated molecu-
lar docking results are 3-hydroxy-1H-quinazoline-2,4-dione
derivatives,46 1-benzyl-1,2,3,4-tetrahydro-b-carboline,47
3-substituted-1H-indoles,48 phenyl-amidine, and triazolyl-
amidine derivatives,49 etc. Since glycine has been identi-
fied as a coagonist of NMDA, there has been a wide search
for finding novel antagonists that could block the glycine
binding NR1 subunit of NMDA receptor.50 Molecular docking
studies have found ifenprodil and similar compounds as
novel blockers of the NR2B unit of NMDA.51,52Novel targets in AD
Muscarinic and nicotinic ACh receptors
Muscarinic receptors (mAChR) are the ACh receptors found
at various locations including the central nervous system
(CNS) that form one of the G protein-receptor complexes in
the cell membranes of certain neurons and other cells. It is
evident that in the CNS, mAChRs are involved in memory,
motor control, and learning process. These receptors are
classified into five subtypes named M1eM5.53 They play
various roles, including acting as the main end-receptor
stimulated by ACh released from postganglionic fibers in
the parasympathetic nervous system. The M1-type mAChR,
in the hippocampus and cerebral cortex, play a central role
in cognitive processing, memory, and learning which are
impaired in AD.53 These cholinergic deficits which become a
significant feature in AD can be restored via cholinergic
activation. A few attempts have been done previously with
muscarinic agonists which improved cognitive functions in
patients but could not complete the trials as they were
nonspecific and activated other subtypes too.54 However,
nicotinic receptors also respond physiologically to ACh and
the a7 and a4b2 subtype expressing neurons are particularly
seen damaged in AD patients.55 Over the years, certain M1
subtype selective agonists such as AF102B, AF150, AF267B,
and AF292 of AF series drugs have been tried on patients with
AD and the compound AF267B has been found to have
excellent pharmacokinetics and can even penetrate the
bloodebrain barrier with oral administration whereas
AF102B, AF150(S), and AF267B were found to have neuro-
trophic effects, elevated nonamyloidogenic APP, and
decreased Ab.56 In AD amyloid formation decreases the
ability of these receptors to transmit signals, thereby lead-
ing to decreased cholinergic activity. It has been reported
that activation of M1 mAChRs can attenuate the Alzheimer’s
pathological features and restore cognitive functions, some
mechanisms upregulate a-APP, and decrease hyper-
phosphorylated tau, since hypocholinergic effects also lead
to formation of Ab.57 An M1 allosteric candidate from
GlaxoSmithKline (Harlow, UK), 77-LH-28-1, has shown great
pharmacological profile and greater CNS penetration. Two
M1 selective agonists, VU0357017 and VU0364572 from
Vanderbilt Centre for Neuroscience Drug Discovery, (Nash-
ville, TN, USA) have been selected and tested on cell line and
animal models and found to be effective on many parame-
ters. But a few of initial M1 agonists also failed after reaching
clinical trial since they were not subtype selective.58 EVP-
6124, an a7 nicotinic receptor agonist developed by Elan
Pharmaceuticals, currently in Phase II trial has shown posi-
tive outcomes in AD patients as a single molecule and as a
combination product with an AChE inhibitor.59
Tau protein
Tau is a microtubule associated protein which plays a vital
role in the assembly and stability of the microtubules which
is one factor in maintaining cell integrity. They are found in
normal phosphorylated soluble form primarily in axons.
These tau proteins become hyperphosphorylated and forms
insoluble intracellular neurofibrillary tangles in neurons in
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plasticity and causes neurodegenerative changes. Glycogen
synthase kinase (GSK-3b or Tau kinase 1) and cdk-5 are some
of the major enzymes involved in hyperphosphorylation of
tau.60,61 Thus, inhibiting GSK-3b and bringing down the
hyperphosphorylation of tau protein has been considered to
be another beneficial therapeutic alternative. Many reputed
pharmaceutical organizations like Eli Lilly (IN, USA), Roche
(Basel, Switzerland), andGlaxoSmithKline (Harlow, UK) have
tried and tested many small molecules as GSK-3b inhibitors.
Maleimide derivatives, oxadiazole, pyrimidine thiazolidine-
diones derivatives, benzimidazoles, imidazopyridines, and
quinolones are some of the most common molecules which
have been recognized for the purpose and have shown pos-
itive results in silico and further in vitro assays.62,63Beta-secretase enzyme
Theb-secretase is the enzyme that initiates the generation of
amyloid beta. It is an attractive drug target for lowering ce-
rebral levels of APP for the treatment of AD. APP is subjected
to degradation via amyloidogenic pathway or via the non-
amyloidogenic pathway. APP is first cleaved either by a-sec-
retase or b-secretase enzymes, and the resultant membrane
attached fragments are processed by g-secretase.4 The
products of a-cleavage followed by g-cleavage are highly
soluble and nonamyloidogenic,5 whereas Ab produced by b
secretase mediated cleavage followed by g-cleavage is bio-
chemically insoluble and prone to polymerization into path-
ological fibrils. Besides, amyloidogenic APP cleavage leads to
the synthesis of a fragment named APP intracellular domain
that alters diverse cellular functions.64 APP synthesized in
the neuronal cell body, primarily undergoes axonal transport
by being contained in transport vesicles. Ab is secreted from
the presynaptic terminals into the extracellular matrix, and
thus fibrillary Ab deposits in AD are formed outside neurons.
FAD mutations on the APP gene either enhance b-cleavage
relative to a-cleavage or alter the activity of g-secretase to
increase the ratio of amyloidogenic Ab42eAb40, which forms
fibrils less rapidly.4 This amyloid processing pathway makes
beta-secretase (memapsin 2 or BACE1) an attractive target
for the development of inhibitors against AD.
BACE 1 is a type 1 transmembrane aspartyl protease and
is predominantly located in the intracellular acidic com-
partments. Their expression is found to be highest in neu-
rons. Interestingly, over-expression and knockdown of
BACE1 increases and decreases the Ab production respec-
tively.64 BACE 1 has two aspartic acid residues in its active
site (since it is an aspartyl protease) namely Asp32 and
Asp228 present in the large hydrophobic cleft. Two
conserved water molecules play an important role in
maintaining the enzymatic stability and function.65 The
molecular docking based approach generated two first
generation BACE1 inhibitors namely OM99-2 and OM00-3
which mimicked the natural substrate.66 Some other re-
ported inhibitors are the modified molecules based on the
parent structure of hydroxyethylene (HE), hydrox-
yethyleneamine (HEA), carbinamine, macrocyclic, acyl-
guanidine, aminoimidazole, and aminoquinazoline.67
Synthetic coumarin derivatives were the first reported
compounds which were computationally validated to bedual inhibitors of AChE and BACE1.68,69 Using docking
studies, some dual inhibitors of AChE and BACE1 have been
generated using HE, HEA, and hydroxymethylcarbonyl as
the scaffolds and two compounds even exhibited excellent
activity in cell based assays.70 In another computational
study, flavonols and flavones namely quercetin, kaemp-
ferol, myricetin, morin, and apigenin have been validated
to be potent BACE 1 inhibitors.71 The most effective pep-
tidomimetic BACE1 inhibitors have been the statine-based
structures with great binding efficacy and IC50 values.
72In silico identified therapeutic molecules
validated through in vitro and in vivo studies
Flavonoid derivatives have been tested in vitro on rat AChE
and shown better inhibitory activity than the marketed drug
rivasttigmine,while a few demonstrated inhibitory activities
similar to donepezil.33 Nordihydroguaiaretic acid, a phenolic
lignin isolated from Larrea tridentates, has been shown to
be a cholinesterase inhibitor similar in activity to the mar-
keted drugs and even has an additional antiaggregation ef-
fect on Ab.73 Many novel carbamates designed and
synthesized chemically have shown better AChE inhibitory
activity than the already present rivastigmine.35 One group
has demonstrated that certain pyridopyrimidine derivatives
have approximately 2e2.5 folds higher AChE inhibitory ac-
tivity than the drug galantamine, demonstrated through the
in vitro enzyme assay.36 Certain pyridonepezil derivatives
have been shown to be better and selective AChE inhibitors
than the reference compound donepezil.37 One recent study
proposed that derivatives of 4-hydroxycoumarins displayed
significant AChE inhibitory activity.74 Novel piperidine de-
rivatives demonstrated to have dual inhibitory activity
against both AChE and Ab aggregation in in vitro assay.75 In a
major breakthrough study, 6-chloro-pyridonepezils have
shown to have dual inhibitory activity against AChE at both
the catalytic site and PAS.38 Significant dual site inhibitory
effect was also shown by certain piperzine derivatives.39 All
the above enzymatic assays were done according to the
established Ellman’s method which uses the thiocholine
(released from AChE degradation) reduced Ellman’s reagent
for spectrometric analysis.39
HE was used as scaffold and its novel derivatives have
been shown to have a dual inhibition action against BACE1
and AChE both.70 Flavonols and flavones especially myricetin
and quercetin exhibited very good cell-free BACE1 inhibitory
effect. Neuronal BACE1 secretion and extracellular Ab con-
centration was significantly reduced after administration of
myricetin and quercetin.71 In another study, modified
benzodiazepine molecules displayed a good BACE1 inhibition
in cell based assay.76 Orally effective HEA derivatives were
shown to have a significant BACE1 inhibition in a preclinical
animalmodel.77 TAK-070, a novel nonpeptide BACE1 inhibitor
compoundwas developed by Takeda Pharmaceuticals Japan,
demonstrated significant Ab lowering activity in a mouse
model.78 Another compound AZD3293, a BACE1 inhibitor by
Astra Zeneca (London, UK), is presently in a Phase 1 clinical
trial.79 Merck & Co., Kenilworth, NJ, USA has also brought an
MK-8931 against BACE1 into a Phase 3 clinical trial.80
The M1 muscarinic agonist AF267B (NGX267 by Torrey
Pines Therapeutics, Inc., CA, USA) decreased Ab levels and
Table 1 Available drugs, targets, and clinical trial molecules for Alzheimer’s disease
S.
No.
Drug target Molecules/drugs Mechanism of action Current status
1. AChE Tacrine, donepezil, rivastigmine,
galantamine
Acetylcholinesterase inhibitor Generic form marketed
by many companies
2. Beta-secretase MK-8931, TAK-070, AZD3293, b-site amyloid precursor
protein cleaving
Phase III trial; Phase I trial
3. Muscarinic (mAChR)/
nicotinic (nAChR) receptor
AF267B, AF102B, 77-LH-28-1,
VU0357017, VU0364572, EVP-6124
activators of specific mAChR
(M1 & M4) & nAChR (a7 & a2b4)
Preclinical trials; Phase II
clinical trial
4. N-methyl D-aspartate
(NMDA)
Memantine, nameda, axura
& akatinol, ebixa, & abixa
N-methyl D-aspartate
(NMDA) antagonist
Generic form marketed
by many companies
5. Tau aggregation LMTX Inhibition of aggregation
of tau
Phase III trial by TauRx
Therapeutics
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mouse models. Long term treatment with AF102B in AD pa-
tients decreased the level of Ab in cerebrospinal fluid.81 In
the search for novel agonists for M1 receptors, allosteric
sites have become inevitable targets. Since these sites are
highly conserved, the ligands have to be very specific in
structure and action. These allosteric agonists should
enhance the binding of orthostatic site agonists. A few ex-
amples of such M1 allosteric agonists developed and are
either in preclinical or clinical trial are AC-42, AC-260584
(piperidine derivative fromAcadia Pharmaceuticals Inc., CA,
USA in preclinical trials), 77-LH-28-1 (GlaxoSmith Kline,
Harlow, UK), TBPB, and BCQA (Merck & Co. Inc.).81 Besides
the BACE1 inhibitors, certain g-secretase inhibitors like
begacestat, BMS-708163 and PF-3084014 have alsomade it to
clinical trials.81 In case of tau hyperphosphorylation and
aggregation, methylene blue (Rember, TauRx Therapeutics
Ltd, Singapore) has shown great results in Phase 2 trials by
preventing aggregation and it also decreased Ab levels in a
mouse model. Lithium chloride, in controlled range, has
shown to be a good GSK-3 inhibitor.81 Another synthetic py-
rimidine derivative [6-(4-pyridyl) pyrimidin-4(3H)-one] has
been shown very effective in silico and in vivo mouse assay
with great CNS penetration.62 TauRx Therapeutics has also
announced Phase 3 trials of its investigational drug LMTX
(TRx 0237, TauRx Therapeutics Ltd, Singapore) which is
chemically methylthioninium chloride where this drug help
inhibiting the tau aggregation in the neurons.82,83 (Table 1).Discussion
The aim of molecular docking is the accurate prediction of
the structure of a ligand within the constraints of a receptor
binding site and to correctly estimate the strength of bind-
ing. To explore effective drugs for the treatment of AD,
different compounds against known and novel targets of AD
could be designed and investigated using molecular docking.
Dual or multiple inhibitors that inhibits two or more targets
of AD may also be investigated. Currently there is no treat-
ment to prevent or cure AD but several approved drugs can
treat some of the symptoms and cause a modest and tem-
porary improvement in memory. Targeting the direct cause
of neuronal degeneration would constitute a rational strat-
egy and hopefully offer better prospects for the treatment ofAD. Several molecules for the above discussed targets have
been withdrawn even from the clinical trials either due to
their ineffectiveness in human trials or their nonspecificity
for receptors. The brain, being the most complex organ, is
difficult in terms of its structural accessibility and the
presence of the bloodebrain barrier and thus difficult for
many in vitro molecules to be effective in situ. Therefore,
special attention should be paid for the development of
effective ligands against the potent targets of AD. In a nut
shell, molecular modeling and docking would be a promising
aspect for novel drug design andwould shorten the time span
of drug discovery that could be further explored as possible
therapeutic interventions for AD.Acknowledgments
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